According to Eagle Pharmaceuticals 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.193706. At the end of 2023 the company had a P/S ratio of 0.9881.
Year | P/S ratio | Change |
---|---|---|
2023 | 0.9881 | -17.77% |
2022 | 1.20 | -68.65% |
2021 | 3.83 | 18.63% |
2020 | 3.23 | -22.71% |
2019 | 4.18 | 59.07% |
2018 | 2.63 | -21.96% |
2017 | 3.37 | -48.03% |
2016 | 6.48 | -69.05% |
2015 | 20.9 | 84.82% |
2014 | 11.3 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | 3.91 | 1,916.80% | ๐บ๐ธ USA |
![]() Novartis NVS | 4.34 | 2,142.21% | ๐จ๐ญ Switzerland |
![]() Eli Lilly LLY | 23.2 | 11,894.98% | ๐บ๐ธ USA |
![]() Amgen AMGN | 5.42 | 2,700.27% | ๐บ๐ธ USA |
![]() Bristol-Myers Squibb BMY | 1.83 | 846.88% | ๐บ๐ธ USA |
![]() GlaxoSmithKline GSK | 2.15 | 1,010.17% | ๐ฌ๐ง UK |
![]() Teva Pharmaceutical Industries TEVA | 1.21 | 527.00% | ๐ฎ๐ฑ Israel |